Msd R&d (china) Co., Ltd.

This study tests a new drug, MK-1045, for people with a type of blood cancer (B-cell acute lymphoblastic leukemia) that has come back or stopped responding to treatment. The trial has two parts: first, finding a safe and tolerable dose, then checking how well it works. About 203 …

This early-phase study tests MK-1045, an immunotherapy that helps the immune system fight cancer, in people with B-cell Non-Hodgkin lymphoma that has returned or stopped responding to treatment. About 100 participants will receive the drug to find the safest dose and check for si…